<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD04800000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P43235</UniProt_ID>
  <Seq_Length>329</Seq_Length>
  <Molecule_Weight>36966</Molecule_Weight>
  <KEGG_ID>hsa:1513</KEGG_ID>
  <Orthology_ID>K01371</Orthology_ID>
  <Function_Summary>Closely involved in osteoclastic bone resorption and may participate partially in the disorder of bone remodeling. Displays potent endoprotease activity against fibrinogen at acid pH. May play an important role in extracellular matrix degradation.</Function_Summary>
  <Catalytic_Mechanism>Broad proteolytic activity. With small-molecule substrates and inhibitors, the major determinant of specificity is P2, which is preferably Leu, Met </Catalytic_Mechanism>
  <Pfam_ID>PF08246:Inhibitor_I29@@PF00112:Peptidase_C1</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>1</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>8</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Cathepsin O2</Alias>
      <Alias>Cathepsin O</Alias>
      <Alias>Cathepsin X</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of peptide bonds in a polypeptide chain by a mechanism in which the sulfhydryl group of a cysteine residue at the active center acts as a nucleophile.</Detail>
      <Keyword>Cysteine-type peptidase activity</Keyword>
      <Ontology_ID>GO:0008234</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of a peptide bond. A peptide bond is a covalent bond formed when the carbon atom from the carboxyl group of one amino acid shares electrons with the nitrogen atom from the amino group of a second amino acid.</Detail>
      <Keyword>Peptidase activity</Keyword>
      <Ontology_ID>GO:0008233</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of internal, alpha-peptide bonds in a polypeptide chain by a mechanism in which the sulfhydryl group of a cysteine residue at the active center acts as a nucleophile.</Detail>
      <Keyword>Cysteine-type endopeptidase activity</Keyword>
      <Ontology_ID>GO:0004197</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of various bonds, e.g. C-O, C-N, C-C, phosphoric anhydride bonds, etc. Hydrolase is the systematic name for any enzyme of EC class 3.</Detail>
      <Keyword>Hydrolase activity</Keyword>
      <Ontology_ID>GO:0016787</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>309</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>146</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>79</Position>
      <Original>Gly</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>277</Position>
      <Original>Ala</Original>
      <Variation>Val</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>The hydrolysis of proteins into smaller polypeptides and/or amino acids by cleavage of their peptide bonds.</Detail>
      <Keyword>Proteolysis</Keyword>
      <Ontology_ID>GO:0006508</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Innate immune responses are defense responses mediated by germline encoded components that directly recognize components of potential pathogens.</Detail>
      <Keyword>Innate immune response</Keyword>
      <Ontology_ID>GO:0045087</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <Molecule_Seq>
    <Protein_Seq>MWGLKVLLLPVVSFALYPEEILDTHWELWKKTHRKQYNNKVDEISRRLIWEKNLKYISIHNLEASLGVHTYELAMNHLGDMTSEEVVQKMTGLKVPLSHSRSNDTLYIPEWEGRAPDSVDYRKKGYVTPVKNQGQCGSCWAFSSVGALEGQLKKKTGKLLNLSPQNLVDCVSENDGCGGGYMTNAFQYVQKNRGIDSEDAYPYVGQEESCMYNPTGKAAKCRGYREIPEGNEKALKRAVARVGPVSVAIDASLTSFQFYSKGVYYDESCNSDNLNHAVLAVGYGIQKGNKHWIIKNSWGENWGNKGYILMARNKNNACGIANLASFPKM</Protein_Seq>
    <DNA_Seq>ACACATGCTGCATACACACAGAAACACTGCAAATCCACTGCCTCCTTCCCTCCTCCCTACCCTTCCTTCTCTCAGCATTTCTATCCCCGCCTCCTCCTCTTACCCAAATTTTCCAGCCGATCACTGGAGCTGACTTCCGCAATCCCGATGGAATAAATCTAGCACCCCTGATGGTGTGCCCACACTTTGCTGCCGAAACGAAGCCAGACAACAGATTTCCATCAGCAGGATGTGGGGGCTCAAGGTTCTGCTGCTACCTGTGGTGAGCTTTGCTCTGTACCCTGAGGAGATACTGGACACCCACTGGGAGCTATGGAAGAAGACCCACAGGAAGCAATATAACAACAAGGTGGATGAAATCTCTCGGCGTTTAATTTGGGAAAAAAACCTGAAGTATATTTCCATCCATAACCTTGAGGCTTCTCTTGGTGTCCATACATATGAACTGGCTATGAACCACCTGGGGGACATGACCAGTGAAGAGGTGGTTCAGAAGATGACTGGACTCAAAGTACCCCTGTCTCATTCCCGCAGTAATGACACCCTTTATATCCCAGAATGGGAAGGTAGAGCCCCAGACTCTGTCGACTATCGAAAGAAAGGATATGTTACTCCTGTCAAAAATCAGGGTCAGTGTGGTTCCTGTTGGGCTTTTAGCTCTGTGGGTGCCCTGGAGGGCCAACTCAAGAAGAAAACTGGCAAACTCTTAAATCTGAGTCCCCAGAACCTAGTGGATTGTGTGTCTGAGAATGATGGCTGTGGAGGGGGCTACATGACCAATGCCTTCCAATATGTGCAGAAGAACCGGGGTATTGACTCTGAAGATGCCTACCCATATGTGGGACAGGAAGAGAGTTGTATGTACAACCCAACAGGCAAGGCAGCTAAATGCAGAGGGTACAGAGAGATCCCCGAGGGGAATGAGAAAGCCCTGAAGAGGGCAGTGGCCCGAGTGGGACCTGTCTCTGTGGCCATTGATGCAAGCCTGACCTCCTTCCAGTTTTACAGCAAAGGTGTGTATTATGATGAAAGCTGCAATAGCGATAATCTGAACCATGCGGTTTTGGCAGTGGGATATGGAATCCAGAAGGGAAACAAGCACTGGATAATTAAAAACAGCTGGGGAGAAAACTGGGGAAACAAAGGATATATCCTCATGGCTCGAAATAAGAACAACGCCTGTGGCATTGCCAACCTGGCCAGCTTCCCCAAGATGTGACTCCAGCCAGCCAAATCCATCCTGCTCTTCCATTTCTTCCACGATGGTGCAGTGTAACGATGCACTTTGGAAGGGAGTTGGTGTGCTATTTTTGAAGCAGATGTGGTGATACTGAGATTGTCTGTTCAGTTTCCCCATTTGTTTGTGCTTCAAATGATCCTTCCTACTTTGCTTCTCTCCACCCATGACCTTTTTCACTGTGGCCATCAGGACTTTCCCTGACAGCTGTGTACTCTTAGGCTAAGAGATGTGACTACAGCCTGCCCCTGACTGTGTTGTCCCAGGGCTGATGCTGTACAGGTACAGGCTGGAGATTTTCACATAGGTTAGATTCTCATTCACGGGACTAGTTAGCTTTAAGCACCCTAGAGGACTAGGGTAATCTGACTTCTCACTTCCTAAGTTCCCTTCTATATCCTCAAGGTAGAAATGTCTATGTTTTCTACTCCAATTCATAAATCTATTCATAAGTCTTTGGTACAAGTTTACATGATAAAAAGAAATGTGATTTGTCTTCCCTTCTTTGCACTTTTGAAATAAAGTATTTATCTCCTGTCTACAGTTTAATAAATAGCATCTAGTACACATTCAAAAAAAAAAAAAAAA</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Bones</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Lysosome</CellLocal>
      <Ontology_ID>GO:0005764</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>CTSK</Gene_Name>
    <Gene_Alias>CTSO; CTSO2</Gene_Alias>
    <Gene_ID>1513</Gene_ID>
    <Genbank_ACCN>NM_000396</Genbank_ACCN>
    <Protein_ACCN>NP_000387</Protein_ACCN>
    <HGNC_ID>2536</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/1513</Gene_URL>
    <UCSC_ID>uc001evp.2</UCSC_ID>
    <EMBL_ID>ENSG00000143387</EMBL_ID>
  </Gene>
  <Disease_List>
    <Disease>
      <Disease_Name>Osteoporosis</Disease_Name>
      <Disease_Detail>Osteoporosis</Disease_Detail>
      <Disease_DB>OST002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/osteoporosis?search=CTSK#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Root Resorption</Disease_Name>
      <Disease_Detail>Root Resorption</Disease_Detail>
      <Disease_DB>RTR008</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/root_resorption?search=CTSK#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Osteoarthritis</Disease_Name>
      <Disease_Detail>Osteoarthritis</Disease_Detail>
      <Disease_DB>OST012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/osteoarthritis?search=CTSK#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Breast Adenocarcinoma</Disease_Name>
      <Disease_Detail>Breast Cancer</Disease_Detail>
      <Disease_DB>BRS044</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/breast_adenocarcinoma?search=CTSK#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Osteomyelitis</Disease_Name>
      <Disease_Detail>Osteomyelitis</Disease_Detail>
      <Disease_DB>OST017</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/osteomyelitis?search=CTSK#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Short Stature</Disease_Name>
      <Disease_Detail>Short Stature</Disease_Detail>
      <Disease_DB>SHR002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/short_stature?search=CTSK#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Arthritis</Disease_Name>
      <Disease_Detail>Arthritis</Disease_Detail>
      <Disease_DB>ART022</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/arthritis?search=CTSK#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Atherosclerosis</Disease_Name>
      <Disease_Detail>Atherosclerosis</Disease_Detail>
      <Disease_DB>ATH003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/atherosclerosis?search=CTSK#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Autosomal Recessive Disease</Disease_Name>
      <Disease_Detail>Autosomal Recessive Disease</Disease_Detail>
      <Disease_DB>ATS010</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/autosomal_recessive_disease?search=CTSK#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Al Amyloidosis</Disease_Name>
      <Disease_Detail>Al Amyloidosis</Disease_Detail>
      <Disease_DB>ALM001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/al_amyloidosis?search=CTSK#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pycnodysostosis</Disease_Name>
      <Disease_Detail>Pycnodysostosis</Disease_Detail>
      <Disease_DB>PYC001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pycnodysostosis?search=CTSK#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Rheumatoid Arthritis</Disease_Name>
      <Disease_Detail>Rheumatoid Arthritis</Disease_Detail>
      <Disease_DB>RHM011</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/rheumatoid_arthritis?search=CTSK#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Osteosclerosis</Disease_Name>
      <Disease_Detail>Osteosclerosis</Disease_Detail>
      <Disease_DB>OST019</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/osteosclerosis?search=CTSK#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Crystal Structure of the Cysteine Protease Human Cathepsin K in Complex with the Covalent Inhibitor NVP-ABE854</PDB_Title>
      <PDB_ID>1U9V</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1U9V</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Novel purine nitrile derived inhibitors of the cysteine protease cathepsin K</PubMed_Title>
      <Author>Altmann, E., et al.</Author>
      <Journal>J.Med.Chem.(2004)47:5833-5836</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15537340?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Cathepsin K complexed with a cyanopyrrolidine inhibitor</PDB_Title>
      <PDB_ID>1YK7</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1YK7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Novel and potent cyclic cyanamide-based cathepsin K inhibitors.</PubMed_Title>
      <Author>Deaton, D.N., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2005)15:1815-1819</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15780613?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Cathepsin K complexed with a ketoamide inhibitor</PDB_Title>
      <PDB_ID>1TU6</PDB_ID>
      <Resolution>1.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1TU6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Potent and selective P2-P3 ketoamide inhibitors of cathepsin K with improved pharmacokinetic properties via favorable P1', P1, and/or P3 substitutions</PubMed_Title>
      <Author>Barrett, D.G., et al.</Author>
      <Journal>BIOORG.MED.CHEM.LETT.(2004)14:4897-4902</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15341947?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Cathepsin K in complex with a non-selective 2-cyano-pyrimidine inhibitor</PDB_Title>
      <PDB_ID>3KWZ</PDB_ID>
      <Resolution>1.49</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3KWZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Cathepsin K covalently bound to a cyano-pyrimidine inhibitor with improved selectivity over hERG</PDB_Title>
      <PDB_ID>3O0U</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3O0U</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Optimisation of 2-cyano-pyrimidine inhibitors of cathepsin K: improving selectivity over hERG.</PubMed_Title>
      <Author>Rankovic, Z., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2010)20:6237-6241</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20843687?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of a pyrrolopyrimidine inhibitor in complex with human Cathepsin K</PDB_Title>
      <PDB_ID>2R6N</PDB_ID>
      <Resolution>1.95</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2R6N</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Novel scaffold for cathepsin K inhibitors.</PubMed_Title>
      <Author>Teno, N., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2007)17:6096-6100</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17911019?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH A COVALENT PYRROLIDINONE INHIBITOR</PDB_Title>
      <PDB_ID>1AU3</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1AU3</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Conformationally constrained 1,3-diamino ketones: a series of potent inhibitors of the cysteine protease cathepsin K.</PubMed_Title>
      <Author>Marquis, R.W., et al.</Author>
      <Journal>J.Med.Chem.(1998)41:3563-3567</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9733481?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH A COVALENT PEPTIDOMIMETIC INHIBITOR</PDB_Title>
      <PDB_ID>1BGO</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1BGO</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Use of X-Ray Co-Crystal Structures and Molecular Modeling to Design Potent and Selective Non-Peptide Inhibitors of Cathepsin K</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Cathepsin K in complex with a selective 2-cyano-pyrimidine inhibitor</PDB_Title>
      <PDB_ID>3KX1</PDB_ID>
      <Resolution>1.51</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3KX1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>The crystal structure of the cathepsin K Variant M5 in complex with chondroitin-4-sulfate</PDB_Title>
      <PDB_ID>3H7D</PDB_ID>
      <Resolution>2.24</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3H7D</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The crystal structure of the cathepsin K Variant M5 in complex with chondroitin-4-sulfate</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Cathepsin K in complex with a covalent inhibitor with a ketoamide warhead</PDB_Title>
      <PDB_ID>3OVZ</PDB_ID>
      <Resolution>2.02</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3OVZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Trifluoromethylphenyl as P2 for ketoamide-based cathepsin S inhibitors.</PubMed_Title>
      <Author>Cai, J., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2010)20:6890-6894</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21030256?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH A COVALENT PYRROLIDINONE INHIBITOR</PDB_Title>
      <PDB_ID>1AU4</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1AU4</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Conformationally constrained 1,3-diamino ketones: a series of potent inhibitors of the cysteine protease cathepsin K.</PubMed_Title>
      <Author>Marquis, R.W., et al.</Author>
      <Journal>J.Med.Chem.(1998)41:3563-3567</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9733481?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Cysteine Protease Human Cathepsin K in Complex with the Covalent Inhibitor NVP-ABJ688</PDB_Title>
      <PDB_ID>1U9X</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1U9X</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Novel purine nitrile derived inhibitors of the cysteine protease cathepsin K</PubMed_Title>
      <Author>Altmann, E., et al.</Author>
      <Journal>J.Med.Chem.(2004)47:5833-5836</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15537340?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Cathepsin K complexed with a cyanamide-based inhibitor</PDB_Title>
      <PDB_ID>1YK8</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1YK8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Acyclic cyanamide-based inhibitors of cathepsin K.</PubMed_Title>
      <Author>Barrett, D.G., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2005)15:3039-3043</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15896958?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Cathepsin K complexed with t-butyl(1S)-1-cyclohexyl-2-oxoethylcarbamate</PDB_Title>
      <PDB_ID>1Q6K</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1Q6K</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Exploration of the P1 SAR of aldehyde cathepsin K inhibitors</PubMed_Title>
      <Author>Catalano, J.G., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2004)14:275-278</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/14684342?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE CRYSTAL STRUCTURE OF HUMAN PROCATHEPSIN K</PDB_Title>
      <PDB_ID>1BY8</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1BY8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The crystal structure of human procathepsin K.</PubMed_Title>
      <Author>LaLonde, J.M., et al.</Author>
      <Journal>Biochemistry(1999)38:862-869</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9893980?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH A COVALENT PROPANONE INHIBITOR</PDB_Title>
      <PDB_ID>1AU2</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1AU2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure and Design of Potent and Selective Cathepsin K Inhibitors</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Cysteine Protease Human Cathepsin K in Complex with the Covalent Inhibitor NVP-ABI491</PDB_Title>
      <PDB_ID>1U9W</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1U9W</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Novel purine nitrile derived inhibitors of the cysteine protease cathepsin K</PubMed_Title>
      <Author>Altmann, E., et al.</Author>
      <Journal>J.Med.Chem.(2004)47:5833-5836</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15537340?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF WILD TYPE HUMAN PROCATHEPSIN K</PDB_Title>
      <PDB_ID>7PCK</PDB_ID>
      <Resolution>3.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=7PCK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of wild-type human procathepsin K.</PubMed_Title>
      <Author>Sivaraman, J., et al.</Author>
      <Journal>Protein Sci.(1999)8:283-290</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10048321?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Cathepsin K complexed with a semicarbazone inhibitor</PDB_Title>
      <PDB_ID>2AUZ</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2AUZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors?</PubMed_Title>
      <Author>Adkison, K.K., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2006)16:978-983</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16290936?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH A COVALENT BENZYLOXYBENZOYLCARBOHYDRAZIDE INHIBITOR</PDB_Title>
      <PDB_ID>1AYW</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1AYW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design of potent and selective human cathepsin K inhibitors that span the active site.</PubMed_Title>
      <Author>Thompson, S.K., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(1997)94:14249-14254</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9405598?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of Cathepsin K complexed with a potent vinyl sulfone inhibitor</PDB_Title>
      <PDB_ID>1MEM</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1MEM</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of human cathepsin K complexed with a potent inhibitor.</PubMed_Title>
      <Author>McGrath, M.E., et al.</Author>
      <Journal>Nat.Struct.Biol.(1997)4:105-109</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9033587?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Cathepsin K complexed with a pyrrolidine ketoamide-based inhibitor</PDB_Title>
      <PDB_ID>2BDL</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2BDL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors.</PubMed_Title>
      <Author>Barrett, D.G., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2006)16:1735-1739</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16376075?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Cathepsin K complexed with carbamate derivatized norleucine aldehyde</PDB_Title>
      <PDB_ID>1SNK</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1SNK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Exploration of the P(2)-P(3) SAR of aldehyde cathepsin K inhibitors</PubMed_Title>
      <Author>Boros, E.E., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2004)14:3425-3429</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15177446?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH A COVALENT AZEPANONE INHIBITOR</PDB_Title>
      <PDB_ID>1NLJ</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1NLJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Azepanone-Based Inhibitors of Human and Rat Cathepsin K</PubMed_Title>
      <Author>Marquis, R.W., et al.</Author>
      <Journal>J.Med.Chem.(2001)44:1380-1395</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11311061?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Cathepsin K complexed with a semicarbazone inhibitor</PDB_Title>
      <PDB_ID>2AUX</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2AUX</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors?</PubMed_Title>
      <Author>Adkison, K.K., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2006)16:978-983</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16290936?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure Of The Cysteine Protease Human Cathepsin K In Complex With A Covalent Azepanone Inhibitor</PDB_Title>
      <PDB_ID>1NL6</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1NL6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Azepanone-based inhibitors of human and rat cathepsin K</PubMed_Title>
      <Author>Marquis, R.W., et al.</Author>
      <Journal>J.Med.Chem.(2001)44:1380-1395</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11311061?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of a potent small molecule inhibitor bound to cathepsin K</PDB_Title>
      <PDB_ID>1VSN</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1VSN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Identification of a potent and selective non-basic cathepsin K inhibitor.</PubMed_Title>
      <Author>Li, C.S., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2006)16:1985-1989</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16413777?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human cathepsin K mutant C25S in complex with an allosteric modifier</PDB_Title>
      <PDB_ID>4LEG</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4LEG</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD04800001</ASD_Ligand>
      <PubMed_Title>A novel allosteric mechanism in the cysteine peptidase cathepsin K discovered by computational methods.</PubMed_Title>
      <Author>Novinec, M., et al.</Author>
      <Journal>Nat Commun(2014)5:3287-3287</Journal>
      <PubMed_ID>24518821</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH A COVALENT THIAZOLHYDRAZIDE INHIBITOR</PDB_Title>
      <PDB_ID>1AYV</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1AYV</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design of potent and selective human cathepsin K inhibitors that span the active site.</PubMed_Title>
      <Author>Thompson, S.K., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(1997)94:14249-14254</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9405598?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of CatK covalently bound to a dioxo-triazine inhibitor</PDB_Title>
      <PDB_ID>3KWB</PDB_ID>
      <Resolution>2.02</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3KWB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Dioxo-triazines as a novel series of cathepsin K inhibitors</PubMed_Title>
      <Author>Rankovic, Z., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2010)20:1488-1490</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20153187?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of Human Cathepsin K in complex with myocrisin</PDB_Title>
      <PDB_ID>2ATO</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ATO</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Effects of disease-modifying anti-rheumatic drugs (DMARDs) on the activities of rheumatoid arthritis-associated cathepsins K and S.</PubMed_Title>
      <Author>Weidauer, E., et al.</Author>
      <Journal>Biol.Chem.(2007)388:331-336</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17338641?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Cathepsin K complexed with a constrained ketoamide inhibitor</PDB_Title>
      <PDB_ID>1YT7</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1YT7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>P(2)-P(3) conformationally constrained ketoamide-based inhibitors of cathepsin K.</PubMed_Title>
      <Author>Barrett, D.G., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2005)15:3540-3546</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15982880?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH THE COVALENT INHIBITOR E-64</PDB_Title>
      <PDB_ID>1ATK</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ATK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of human osteoclast cathepsin K complex with E-64.</PubMed_Title>
      <Author>Zhao, B., et al.</Author>
      <Journal>Nat.Struct.Biol.(1997)4:109-111</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9033588?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Cathepsin K covalently bound to a 2-cyano pyrimidine inhibitor with a benzyl P3 group.</PDB_Title>
      <PDB_ID>3O1G</PDB_ID>
      <Resolution>1.65</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3O1G</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Optimisation of 2-cyano-pyrimidine inhibitors of cathepsin K: improving selectivity over hERG.</PubMed_Title>
      <Author>Rankovic, Z., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2010)20:6237-6241</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20843687?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH A COVALENT SYMMETRIC DIACYLAMINOMETHYL KETONE INHIBITOR</PDB_Title>
      <PDB_ID>1AU0</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1AU0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure and Design of Potent and Selective Cathepsin K Inhibitors</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the cathepsin K : chondroitin sulfate complex.</PDB_Title>
      <PDB_ID>3C9E</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3C9E</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The crystal and molecular structures of a cathepsin K:chondroitin sulfate complex.</PubMed_Title>
      <Author>Li, Z., et al.</Author>
      <Journal>J.Mol.Biol.(2008)383:78-91</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18692071?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-ray structure of Cathepsin K covalently bound to a triazine ligand</PDB_Title>
      <PDB_ID>3KW9</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3KW9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF CYSTEINE PROTEASE HUMAN CATHEPSIN K IN COMPLEX WITH A COVALENT SYMMETRIC BISCARBOHYDRAZIDE INHIBITOR</PDB_Title>
      <PDB_ID>1AYU</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1AYU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design of potent and selective human cathepsin K inhibitors that span the active site.</PubMed_Title>
      <Author>Thompson, S.K., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(1997)94:14249-14254</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9405598?dopt=Abstract</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04380</Pathway_ID>
      <Pathway_Title>Osteoclast differentiation</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Development</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04620</Pathway_ID>
      <Pathway_Title>Toll-like receptor signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>Alpha and beta proteins (a+b)</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.e.d.b.b.ca.html</SCOP_URL>
    <CATH_Class>Class 3: Mixed Alpha-Beta</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1atk</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Type>R-T transition</Site_Type>
    </AllostericSite>
  </AllostericSite_List>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>3.4.22.38</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC3/4/22/38.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD04800001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04800002</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04800003</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04800004</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04800005</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04800006</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04800007</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04800008</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04800009</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>